Patents Assigned to Integrated DNA Technologies, Inc.
-
Publication number: 20100075383Abstract: The invention provides compositions and methods for amplifying nucleic acid polymer sequences in a high complexity nucleic acid sample. The unique compositions of the invention include a primer set composed of a mixture of two types of primers for DNA synthesis. For extension in one direction, the primers all contain modifications that destroy their ability to serve as templates that can be copied by DNA polymerases. For extension in the opposite direction the set includes at least one primer that can serve as a template and be replicated by DNA polymerases throughout its length. The method can be carried out by mixing the nucleic acid polymer sequence of interest with the set of DNA synthesis primers in an amplification reaction mixture. The reaction mixture is then subjected to temperature cycling analogous to the temperature cycling in PCR reactions. At least one primer in the primer set hybridizes to the nucleic acid polymer.Type: ApplicationFiled: September 9, 2009Publication date: March 25, 2010Applicant: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Mark A. Behlke, Joseph A. Walder, Jeffrey A. Manthey
-
Publication number: 20100069465Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.Type: ApplicationFiled: August 27, 2009Publication date: March 18, 2010Applicants: CITY OF HOPE, INTEGRATED DNA TECHNOLOGIES, INC.Inventors: John J. ROSSI, Mark A. BEHLKE, Dongho KIM
-
Patent number: 7645872Abstract: The invention provides a novel method of labeling oligonucleotides, with reporter moieties, including but not limited to, quenchers, fluorophores, biotin, digoxigenin, peptides and proteins. In addition, this invention provides a method of detecting hybridization of oligonucleotides. This invention also provides novel azo quenchers having the general formula shown below. The invention further provides compositions comprising labeled oligonucleotides and solid supports. The invention also provides kits comprising at least one composition of the present invention.Type: GrantFiled: August 4, 2009Date of Patent: January 12, 2010Assignee: Integrated DNA Technologies, Inc.Inventors: Andrei Laikhter, Joseph A. Walder, Mark Behlke, Mikhail Podyminogin, Yawfui Yong
-
Publication number: 20100004318Abstract: The invention provides compositions and methods for selectively reducing the expression of a gene product from a desired target gene, as well as treating diseases caused by expression of the gene. The method involves introducing into the environment of a cell an amount of a double-stranded RNA (dsRNA) such that a sufficient portion of the dsRNA can enter the cytoplasm of the cell to cause a reduction in the expression of the target gene. The dsRNA has a first oligonucleotide sequence that is between 26 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of from about 19 to about 23 nucleotides is complementary to a nucleotide sequence of the RNA produced from the target gene.Type: ApplicationFiled: August 28, 2009Publication date: January 7, 2010Applicants: INTEGRATED DNA TECHNOLOGIES, INC., CITY OF HOPEInventors: John J. ROSSI, Mark A. BEHLKE, Dongho KIM
-
Publication number: 20100003758Abstract: The invention provides compositions and methods for selectively reducing the expression of a gene product from a desired target gene, as well as treating diseases caused by expression of the gene. The method involves introducing into the environment of a cell an amount of a double-stranded RNA (dsRNA) such that a sufficient portion of the dsRNA can enter the cytoplasm of the cell to cause a reduction in the expression of the target gene. The dsRNA has a first oligonucleotide sequence that is between 26 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of from about 19 to about 23 nucleotides is complementary to a nucleotide sequence of the RNA produced from the target gene.Type: ApplicationFiled: August 28, 2009Publication date: January 7, 2010Applicants: INTEGRATED DNA TECHNOLOGIES, INC., CITY OF HOPEInventors: John J. ROSSI, Mark A. BEHLKE, Dongho KIM
-
Publication number: 20100004435Abstract: The invention provides compositions and methods for selectively reducing the expression of a gene product from a desired target gene, as well as treating diseases caused by expression of the gene. The method involves introducing into the environment of a cell an amount of a double-stranded RNA (dsRNA) such that a sufficient portion of the dsRNA can enter the cytoplasm of the cell to cause a reduction in the expression of the target gene. The dsRNA has a first oligonucleotide sequence that is between 26 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of from about 19 to about 23 nucleotides is complementary to a nucleotide sequence of the RNA produced from the target gene.Type: ApplicationFiled: August 28, 2009Publication date: January 7, 2010Applicants: INTEGRATED DNA TECHNOLOGIES, INC., CITY OF HOPEInventors: John J. ROSSI, Mark A. BEHLKE, Dongho KIM
-
Publication number: 20100004434Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.Type: ApplicationFiled: August 27, 2009Publication date: January 7, 2010Applicants: CITY OF HOPE, INTEGRATED DNA TECHNOLOGIES, INC.Inventors: John J. ROSSI, Mark A. BEHLKE, Dongho KIM
-
Publication number: 20100004436Abstract: The invention provides compositions and methods for selectively reducing the expression of a gene product from a desired target gene, as well as treating diseases caused by expression of the gene. The method involves introducing into the environment of a cell an amount of a double-stranded RNA (dsRNA) such that a sufficient portion of the dsRNA can enter the cytoplasm of the cell to cause a reduction in the expression of the target gene. The dsRNA has a first oligonucleotide sequence that is between 26 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of from about 19 to about 23 nucleotides is complementary to a nucleotide sequence of the RNA produced from the target gene.Type: ApplicationFiled: August 28, 2009Publication date: January 7, 2010Applicants: INTEGRATED DNA TECHNOLOGIES, INC., CITY OF HOPEInventors: John J. ROSSI, Mark A. BEHLKE, Dongho KIM
-
Publication number: 20100004317Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.Type: ApplicationFiled: August 27, 2009Publication date: January 7, 2010Applicants: CITY OF HOPE, INTEGRATED DNA TECHNOLOGIES, INC.Inventors: John J. ROSSI, Mark A. BEHLKE, Dongho KIM
-
Publication number: 20090325285Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.Type: ApplicationFiled: August 27, 2009Publication date: December 31, 2009Applicants: CITY OF HOPE, INTEGRATED DNA TECHNOLOGIES, INC.Inventors: John J. ROSSI, Mark A. BEHLKE, Dongho KIM
-
Publication number: 20090325286Abstract: The invention provides compositions and methods for selectively reducing the expression of a gene product from a desired target gene, as well as treating diseases caused by expression of the gene. The method involves introducing into the environment of a cell an amount of a double-stranded RNA (dsRNA) such that a sufficient portion of the dsRNA can enter the cytoplasm of the cell to cause a reduction in the expression of the target gene. The dsRNA has a first oligonucleotide sequence that is between 26 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of from about 19 to about 23 nucleotides is complementary to a nucleotide sequence of the RNA produced from the target gene.Type: ApplicationFiled: August 28, 2009Publication date: December 31, 2009Applicants: INTEGRATED DNA TECHNOLOGIES, INC., CITY OF HOPEInventors: John J. ROSSI, Mark A. BEHLKE, Dongho KIM
-
Publication number: 20090325169Abstract: The present invention pertains to novel oligonucleotide compounds for use in various biological assays, such as nucleic acid amplification, ligation and sequencing reactions. The novel oligonucleotides comprise a ribonucleic acid domain and a blocking group at or near the 3? end of the oligonucleotide. These compounds offer an added level of specificity previously unseen. Methods for performing nucleic acid amplification, ligation and sequencing are also provided. Additionally, kits containing the oligonucleotides are also disclosed herein.Type: ApplicationFiled: April 30, 2009Publication date: December 31, 2009Applicant: Integrated DNA Technologies, Inc.Inventors: Joseph Alan Walder, Mark Aaron Behlke, Scott Rose, Joseph Dobosy
-
Publication number: 20090325306Abstract: The invention provides a method for evaluating the accuracy of an oligonucleotide sample, specifically a sample containing a variety of oligonucleotides of potentially varying size and sequence. The method provides a fingerprint that can be used to evaluate the accuracy of a multi-oligonucleotide sample whether or not the sample contains differing oligonucleotides that have the same or about the same molecular weight.Type: ApplicationFiled: September 10, 2009Publication date: December 31, 2009Applicant: INTEGRATED DNA TECHNOLOGIES, INC.Inventor: Brian Elliott
-
Publication number: 20090325181Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.Type: ApplicationFiled: August 27, 2009Publication date: December 31, 2009Applicants: CITY OF HOPE, INTEGRATED DNA TECHNOLOGIES, INC.Inventors: John J. ROSSI, Mark A. BEHLKE, Dongho KIM
-
Publication number: 20090326046Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.Type: ApplicationFiled: August 27, 2009Publication date: December 31, 2009Applicants: CITY OF HOPE, INTEGRATED DNA TECHNOLOGIES, INC.Inventors: John J. ROSSI, Mark A. BEHLKE, Dongho KIM
-
Patent number: 7629152Abstract: The invention provides compositions and methods for amplifying nucleic acid polymer sequences in a high complexity nucleic acid sample. The unique compositions of the invention include a primer set composed of a mixture of two types of primers for DNA synthesis. For extension in one direction, the primers all contain modifications that destroy their ability to serve as templates that can be copied by DNA polymerases. For extension in the opposite direction the set includes at least one primer that can serve as a template and be replicated by DNA polymerases throughout its length. The method can be carried out by mixing the nucleic acid polymer sequence of interest with the set of DNA synthesis primers in an amplification reaction mixture. The reaction mixture is then subjected to temperature cycling analogous to the temperature cycling in PCR reactions. At least one primer in the primer set hybridizes to the nucleic acid polymer.Type: GrantFiled: August 2, 2004Date of Patent: December 8, 2009Assignee: Integrated DNA Technologies, Inc.Inventors: Mark A. Behlke, Joseph A. Walder, Jeffrey A. Manthey
-
Publication number: 20090299041Abstract: The invention provides a novel method of labeling oligonucleotides, with reporter moieties, including but not limited to, quenchers, fluorophores, biotin, digoxigenin, peptides and proteins. In addition, this invention provides a method of detecting hybridization of oligonucleotides. This invention also provides novel azo quenchers having the general formula shown below. The invention further provides compositions comprising labeled oligonucleotides and solid supports. The invention also provides kits comprising at least one composition of the present invention.Type: ApplicationFiled: August 4, 2009Publication date: December 3, 2009Applicant: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Andrei Laikhter, Joseph A. Walder, Mark Behlke, Mikhail Podyminogin, Yawfui Yong
-
Patent number: 7604998Abstract: The invention provides a method for evaluating the accuracy of an oligonucleotide sample, specifically a sample containing a variety of oligonucleotides of potentially varying size and sequence. The method provides a fingerprint that can be used to evaluate the accuracy of a multi-oligonucleotide sample whether or not the sample contains differing oligonucleotides that have the same or about the same molecular weight.Type: GrantFiled: October 23, 2007Date of Patent: October 20, 2009Assignee: Integrated DNA Technologies, IncInventor: Brian Elliott
-
Patent number: 7605243Abstract: The invention provides a novel method of labeling oligonucleotides, with reporter moieties, including but not limited to, quenchers, fluorophores, biotin, digoxigenin, peptides and proteins. In addition, this invention provides a method of detecting hybridization of oligonucleotides. This invention also provides novel azo quenchers having the general formula shown below. The invention further provides compositions comprising labeled oligonucleotides and solid supports. The invention also provides kits comprising at least one composition of the present invention.Type: GrantFiled: January 12, 2009Date of Patent: October 20, 2009Assignee: Integrated DNA Technologies, Inc.Inventors: Andrei Laikhter, Joseph A. Walder, Mark Behlke, Mikhail Podyminogin, Yawfui Yong
-
Publication number: 20090198453Abstract: The invention relates to methods and systems for predicting or estimating the melting temperature of duplex nucleic acids, in the presence of divalent cations, particularly duplexes of oligonucleotides which may be used as, for example, but not limited to primers or probes in PCR and/or hybridization assays. The methods and algorithms use novel formulas, having terms and coefficients that are functions of the particular nucleotide sequence, to estimate the effect of divalent cation salt conditions on the melting temperature.Type: ApplicationFiled: January 7, 2008Publication date: August 6, 2009Applicant: Integrated DNA Technologies, IncInventors: Richard Owczarzy, Bernardo Moreira, Yong You, Mark Aaron Behlke, Joseph Alan Walder